Clearstead Advisors
LYEL icon

Clearstead Advisors’s Lyell Immunopharma LYEL Stock Holding History

Clearstead Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$196K Buy
19,982
+24
+0.1% +$319 ﹤0.01% 1056
2026
Q2 		$280K Sell
19,958
-19,958
-50% -$361K ﹤0.01% 949
2026
Q1 		$801K Buy
+39,916
New +$933K 0.01% 593

Other funds holding LYEL

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Clearstead Advisors's LYEL Position: Q3 2026 in Review

Clearstead Advisors increased its Lyell Immunopharma (LYEL) stake by 0.12% in Q3 2026, buying an estimated $319 and bringing the position to 19,982 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #1056.

Clearstead Advisors first reported a position in LYEL in Q1 2026 and has held it in 3 quarters since. The position peaked at $801K in Q1 2026. 43 funds tracked by Wall St. Rank hold LYEL as of Q3 2026.

  • Clearstead Advisors held 19,982 shares of Lyell Immunopharma worth $196K as of Q3 2026.
  • Clearstead Advisors bought 24 Lyell Immunopharma shares in Q3 2026, an estimated $319.
  • Lyell Immunopharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #1056 holding.
  • Clearstead Advisors first reported a position in Lyell Immunopharma in Q1 2026 and has held it in 3 quarters since.
  • Clearstead Advisors's Lyell Immunopharma position peaked at $801K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.